M Holdings Securities Inc. Buys 340 Shares of Merck & Co., Inc. (NYSE:MRK)

M Holdings Securities Inc. grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,007 shares of the company’s stock after buying an additional 340 shares during the period. M Holdings Securities Inc.’s holdings in Merck & Co., Inc. were worth $1,929,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MRK. NumerixS Investment Technologies Inc increased its position in shares of Merck & Co., Inc. by 138.7% in the second quarter. NumerixS Investment Technologies Inc now owns 32,468 shares of the company’s stock worth $2,722,000 after purchasing an additional 18,868 shares during the last quarter. Girard Partners LTD. increased its position in shares of Merck & Co., Inc. by 2.7% in the second quarter. Girard Partners LTD. now owns 103,298 shares of the company’s stock worth $8,661,000 after purchasing an additional 2,720 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Merck & Co., Inc. by 15.9% in the second quarter. Alps Advisors Inc. now owns 38,470 shares of the company’s stock worth $3,226,000 after purchasing an additional 5,273 shares during the last quarter. Lowe Wealth Advisors LLC increased its position in shares of Merck & Co., Inc. by 12.0% in the second quarter. Lowe Wealth Advisors LLC now owns 1,396 shares of the company’s stock worth $117,000 after purchasing an additional 150 shares during the last quarter. Finally, Capital Financial Planning LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $149,000. Hedge funds and other institutional investors own 74.97% of the company’s stock.

Several research firms recently weighed in on MRK. Credit Suisse Group restated a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Goldman Sachs Group began coverage on shares of Merck & Co., Inc. in a research report on Tuesday, May 28th. They issued a “neutral” rating and a $85.00 price objective on the stock. Societe Generale set a $105.00 price objective on shares of Merck & Co., Inc. and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Morgan Stanley upped their price objective on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 21st. Finally, Leerink Swann began coverage on shares of Merck & Co., Inc. in a research report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price objective on the stock. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $93.29.



In other news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

NYSE MRK traded up $0.09 on Wednesday, reaching $83.69. 155,294 shares of the company’s stock traded hands, compared to its average volume of 8,064,552. Merck & Co., Inc. has a 12 month low of $66.10 and a 12 month high of $87.35. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The stock has a 50-day simple moving average of $84.96 and a 200 day simple moving average of $82.03. The stock has a market cap of $218.04 billion, a PE ratio of 19.32, a P/E/G ratio of 1.73 and a beta of 0.53.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The business had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $10.94 billion. During the same period last year, the business earned $1.06 earnings per share. The business’s quarterly revenue was up 12.4% on a year-over-year basis. As a group, analysts anticipate that Merck & Co., Inc. will post 4.92 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Stockholders of record on Monday, September 16th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: What is the NASDAQ?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.